Q&A: Eikon CEO Roger Perlmutter talks leaving Merck, pharma R&D, growing biotech startup

HAYWARD, Calif. — After Roger Perlmutter stepped down as Merck’s head of R&D in 2021, he took a single weekend off before starting at Eikon Therapeutics, where as CEO he leads one of the industry’s most valuable privately held companies, building microscopes and developing drugs.

Eikon studies the “social lives…
Click here to view original post